| ²é¿´: 230 | »Ø¸´: 1 | ||
ytfscxlгæ (³õÈëÎÄ̳)
|
[ÇóÖú]
¹ýÃôÐÔ»úÖÆ ¿´²»¶®Á½¶ÎÓ¢Óï Çë´óÏÀ½øÀ´¿´¿´
|
|
1.Eicosanoids£ºA family of lipid mediatorswith diverse biologicalactivities. These metabolitesare the products of thelipoxygenase andcyclooxygenase pathways ¡ªwhich produce leukotrienesand prostaglandins,respectively ¡ª and they areimportant mediators of theallergic inflammatory response. ÕâÊÇÀà¶þÊ®ÍéËáµÄ¼ò½é£¬ËûÊÇÒ»ÖÖ¾ßÓв»Í¬ÉúÎïѧ»îÐÔµÄÖ¬ÖʽéÖʵļÒ×å¡£²»¶®ÖмäÒ»¾ämetaboliteºÍwhich·Ö±ðÖ¸´úʲô£¿ËÄÜ˵³ö¸öÏȺó˳Ðò ˲úÉúʲôȻºóÔõôÁË£¿°×ÈýϩǰÁÐÏÙËØºÍÀà¶þÊ®ÍéËáÓÐɶ¹ØÏµõ¥ÑõºÏøºÍ»·ÑõºÏøͨ··Ö±ð¿ÉÒÔ²úÉú°×ÈýÏ©ºÍǰÁÐÏÙËØ£¬ÕâЩÒò×ÓÊǹýÃôÑ×Ö¢·´Ó¦µÄÖØÒª´«µÝÎï¡£ 2.In this Review, we discuss the evidence for these interacting pathways and describe how the capacity of KIT, and other receptors, to influence Fc¦ÅRI-dependent mast-cell-mediator release might be a function ofthe relative abilities of these receptors to activate these alternative pathways. ÕâÊÇÂÛÎÄÀïµÄabstractÖÐ×îºóÒ»¾ä»° ²»¶®×îºóÒ»¾äµÄÒâ˼ ´Óhow¿ªÊ¼ |
» ²ÂÄãϲ»¶
Wnt-C59£ºPORCN°ÐÏò»¯Ñ§Ì½Õ룬WntÐźÅͨ·×è¶Ï»úÖÆÓë¿ÆÑÐÓ¦ÓÃÈ«½âÎö
ÒѾÓÐ0È˻ظ´
Fexaramine£º³¦µÀÏÞÖÆÐÔFXR»¯Ñ§Ì½Õ룬½á¹¹ÌØÕ÷ÓëÐźÅͨ·Ñо¿È«½âÎö
ÒѾÓÐ0È˻ظ´
»¯Ñ§¹¤³Ì¼°¹¤Òµ»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ122È˻ظ´
NVS-STG2£º°ÐÏòSTING¿çĤÓòµÄ·Ö×Ó½ºÀ༤¶¯¼Á£¬½á¹¹ÌØÕ÷Óë¹Ñ¾Û»¯»úÖÆÑо¿È«½âÎö
ÒѾÓÐ0È˻ظ´
DOTA-GPC3ëÄ£¨CAS 3066439-94-6£©£ºË«¹¦ÄÜ·Ö×Ó̽ÕëǰÌåµÄ½á¹¹ÌØÕ÷Óë±ê¼ÇÓ¦ÓýâÎö
ÒѾÓÐ0È˻ظ´
¿ÆÑÐÓà TLR7/8 Ë«¼¤¶¯¼ÁÔõôѡ£¿ÏÖ»õÓëÖÊ¿ØÒªµã
ÒѾÓÐ0È˻ظ´
SEL120-34A HCl£ºCDK8/CDK19¸ßÑ¡ÔñÐÔ¼¤Ã¸ÒÖÖÆ¼Á
ÒѾÓÐ0È˻ظ´
ÇâÑõ»¯¼Ø»î»¯²Ù×÷
ÒѾÓÐ18È˻ظ´
É¢½ð
ÒѾÓÐ68È˻ظ´
ÉúÎïÖʳ¬¼¶µçÈÝÆ÷
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ytfscxl
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 12.3
- Ìû×Ó: 18
- ÔÚÏß: 2.8Сʱ
- ³æºÅ: 2251191
- ×¢²á: 2013-01-20
- רҵ: ÉúÎï¼¼ÊõÒ©Îï
2Â¥2015-03-14 21:24:50









»Ø¸´´ËÂ¥
ͶƱ:
28